Administration of fractional doses of IPV vaccine (fIPV) by
This page has been archived and is no longer updated. We apologize for the inconvenience. To find similar material or an updated version of the page, please visit one of the following resources: Health Topics || Country Sites || News Releases || Our New HomepageThis page has been archived and is no longer updated. We apologize for the inconvenience. To find similar material or an updated version of the page, please visit one of the following resources: Health Topics || Country Sites || News Releases || Our New Homepage
In view of the limited supply of IPV, PAHO’s Immunization Unit considered it appropriate to strengthen compliance with the World Health Organization’s (WHO) Multidose Open Vial Policy.
Special Vaccine Glass
Sabin Polio Vaccine (oral) is a stabilized preparation of live attenuated polioviruses of Sabin type 1 (LS-c, 2ab), type 2 (P 712ch, 2ab) and type 3 (Leon 12a, 1b) strains propagated in human diploid MRC-5 cells.
Each immunizing dose of vaccine contains the following live attenuated poliovirus titers of Sabin strains: not less than 106 DICT50 live attenuated poliovirus type 1, not less than 105 DICT50 live attenuated poliovirus type 2 and not less than 105.5 DICT50 live attenuated poliovirus type 3.
– In the case of travel to highly polio-endemic countries, vaccination may be initiated at birth, rather than at 2 or 3 months of age. If this is the case, 4 doses should be administered for the primary vaccination schedule.
The administration of Polio Sabin (oral) should be postponed in persons suffering from severe acute febrile illness, persistent diarrhea or vomiting. However, the presence of a minor infection is not a contraindication to immunization.
Polio Sabin (oral) is contraindicated in subjects with known hypersensitivity to neomycin or polymyxin or to any other component of the vaccine (see section 6.1 List of excipients). A history of contact dermatitis to neomycin or polymyxin is not a contraindication.
Dilution of Medicine with Ampoule Vial
Calls on the Commission to address the use of mercury in the manufacture of vaccines, as already mentioned in the Council conclusions of 24 June 2005, and to examine the situation with a view to achieving a restriction of this use, or even a total ban as soon as appropriate and safe alternatives become available; also calls for support for research
20. Calls upon the Commission to address the use of mercury in the manufacture of vaccines, as also mentioned in the Council conclusions of 24 June 2005, and to evaluate this with a view to achieving a restriction of such use and a total ban, when appropriate and safe alternatives exist, and to
Do vaccines in Spain have thiomersal/thimerosal?
The vaccines currently purchased by the country are subject to prequalification by the World Health Organization (WHO), which involves, in addition to the performance of complex tests, additional procedures aimed at guaranteeing their quality and safety, such as: characterization of raw materials through audits to suppliers, cell banks, seeding batch systems; requirement of Good Manufacturing Practices, release of batches by the national health authority, Instituto Nacional de Vigilancia de Medicamentos y Alimentos (Invima), as well as pre- and post-marketing surveillance of possible adverse events after the use of these vaccines, by that entity. These procedures contribute to verify the quality, efficacy and safety of the vaccines used in the country.
Vaccine production lead times are often long and require considerable and careful advance planning. In addition, growing global demand for some vaccines can affect the timely supply in the country.